Formulation and Evaluation of Fixed-Dose Combination of Bilayer Gastroretentive Matrix Tablet Containing Atorvastatin as Fast-Release and Atenolol as Sustained-Release

Table 5

Pharmacokinetic parameters for Tonact, Aten, and bilayer tablets (containing 10 mg of atorvastatin and 50 mg of atenolol) after oral administration to healthy rabbit (𝑛=3).

Parameter^a	Tablet
	Tonact	Aten	Bilayer tablet
			Atorvastatin	Atenolol
𝐶max (μg mL^−1)	17.00±4.47	27.53±3.53	18.19±5.10	26.55±8.24
𝑇max (h)	0.52±0.34	3.11±2.21	0.54±0.29	3.08±1.89
AUC0--∞ (μg h mL^−1)	81.04±22.29	342.65±62.82	106.47±31.48	347.12±74.67
AUMC0--∞ (μg h^2 mL^−1)	334.89±79.35	2796.51±52.50	780.37±102.84	2847.31±96.49
MRT (h)	5.29±0.48	8.16±0.15	7.33±0.62	8.20±0.94
𝑡1/2 (h)	3.04±0.41	7.54±0.64	3.31±0.24	9.90±0.55
𝐾el (h^−1)	0.23±0.01	0.10±0.01	0.21±0.03	0.07±0.01

^a𝑇_max: time to reach plasma concentration (𝐶_max); AUC: area under plasma concentration-time curve; AUMC: area under the first momentum plasma concentration-time curve; MRT: mean residence time; 𝑡_1/2: plasma half-life of drug; 𝐾_el: elimination rate constant.